Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ijd.13613 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
IL-27 as a novel biomarker for pruritus in nodular prurigo and bullous pemphigoid.
Front Immunol
December 2024
Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Introduction: Bullous pemphigoid (BP) and prurigo nodularis (PN) are chronic pruritic skin diseases that severely impact patients' quality of life. Despite the widespread attention these two diseases have garnered within the dermatological field, the specific pathogenesis, particularly the molecular mechanisms underlying the pruritus, remains largely unclear. Limited clinical sequencing studies focusing on BP and PN have hindered the identification of pathological mechanisms and the exploration of effective treatment strategies.
View Article and Find Full Text PDFCase report: Low-dose interleukin-2: a treatment of bullous pemphigoid with predominantly perifollicular blistering caused by PD-1/PD-L1 inhibitor.
Front Immunol
December 2024
Department of Dermatology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Objectives: This study aimed to evaluate the efficacy of low-dose interleukin (IL-2) treatment for bullous pemphigoid (BP) caused by anti-programmed cell death protein 1/ligand 1 (PD-1/PD-L1) inhibitors.
Methods: Low-dose IL-2 treatment was standardized for BP. The Bullous Pemphigoid Disease Area Index (BPDAI), 5D-Itch Scale (5D-IS), and Dermatology Life Quality Index (DLQI) were recorded before and after treatment, and hexachromatic lymphocytes, regulatory T cells (Treg cells), and cytokines were measured.
Bullous Pemphigoid Induced by Cefixime: A Rare Side Effect.
Cureus
November 2024
Internal Medicine and Clinical Immunology, Lebanese Hospital Geitaoui - University Medical Center, Beirut, LBN.
Bullous pemphigoid (BP) is the most prevalent autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and manifests with pruritus and localized or, most commonly, generalized bullous lesions. Numerous studies have established the association between BP and oral antidiabetic agents, particularly dipeptidyl peptidase 4 (DPP4) inhibitors, diuretics, and certain antibiotics, notably levofloxacin and cephalexin.
View Article and Find Full Text PDFBullous Pemphigoid Onset Following Vaccination in Infancy: A Case Report.
Cureus
December 2024
Dermatology, Sheffield Children's Hospital, Sheffield, GBR.
Bullous pemphigoid (BP) is a rare autoimmune blistering disease characterised by autoantibodies against basal skin membrane antigens. Although the condition's aetiology remains unclear, recent cases have raised suspicions of an association with immunisation. In this study, we present a case of BP onset in a four-month-old infant following routine vaccination.
View Article and Find Full Text PDFMacrophages in inflammatory skin diseases and skin tumors.
Front Immunol
December 2024
Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Article Synopsis
- - Macrophages are key immune cells that play diverse roles in the body, especially in the skin, which is the largest immune organ and is crucial for studying various skin-related conditions.
- - This review focuses on recent findings about macrophages in inflammatory skin diseases like atopic dermatitis and psoriasis, as well as skin tumors such as melanoma and cutaneous T-cell lymphoma.
- - The goal is to enhance understanding of how macrophages contribute to these diseases and explore potential new treatments targeting them.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!